Genzyme Renagel Growth To Come From Medicare Rx, Kidney Disease Use

Genzyme expects results from a Phase IV Renagel outcomes study to bolster the phosphate binder's long-term growth prospects, Renal Division General Manager John Butler told investors Feb. 19